Clinical Trial Update: A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma [Phase 1]

View source ↗

Summary

A Phase I/Ib multicenter, open-label dose-escalation study of E7080 (lenvatinib) alone and in combination with temozolomide in solid tumors and metastatic melan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• E7080 (lenvatinib)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Eisai Inc. | Conditions: Metastatic Melanoma | Phase 1 | Status: COMPLETED